{
    "name": "glucagon intranasal",
    "comment": "Rx",
    "other_names": [
        "Baqsimi"
    ],
    "classes": [
        "Glucose-Elevating Agents",
        "Hypoglycemia Antidotes"
    ],
    "source": "https://reference.medscape.com/drug/baqsimi-glucagon-intranasal-1000342",
    "pregnancy": {
        "common": [
            "Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There is no information available on the presence of glucagon in human or animal milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production",
            "However, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is therefore unlikely to cause harm to an exposed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pheochromocytoma",
                "Insulinoma",
                "Hypersensitivity to glucagon or to any excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Allergic reactions reported including anaphylactic shock with breathing difficulties and hypotension",
                "Contraindicated with pheochromocytoma; glucagon may stimulate catecholamine release from the tumor; if blood pressure (BP) increases dramatically and undiagnosed pheochromocytoma is suspected, administer phentolamine 5-10 mg IV to lower BP",
                "Contraindicated with insulinoma; glucagon administration may produce initial increase in blood glucose; however, glucagon may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia; treat with glucose PO or IV",
                "Effective for hypoglycemia only if sufficient hepatic glycogen is present; patients in states of starvation, with adrenal insufficiency, or chronic hypoglycemia may not have adequate levels of hepatic glycogen for glucagon to be effective; treat these patients with glucose"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Patients taking beta-blockers may have transiently increased pulse and BP when administered glucagon",
                        "In patients taking indomethacin, glucagon may lose its ability to raise blood glucose or may even produce hypoglycemia",
                        "Glucagon may increase anticoagulant effect of warfarin"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "aclidinium",
            "description": {
                "common": "glucagon intranasal increases toxicity of aclidinium by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atropine",
            "description": {
                "common": "glucagon intranasal increases effects of atropine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benztropine",
            "description": {
                "common": "glucagon intranasal increases toxicity of benztropine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dicyclomine",
            "description": {
                "common": "glucagon intranasal increases toxicity of dicyclomine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glycopyrrolate",
            "description": {
                "common": "glucagon intranasal increases toxicity of glycopyrrolate by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glycopyrrolate inhaled",
            "description": {
                "common": "glucagon intranasal increases toxicity of glycopyrrolate inhaled by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hyoscyamine",
            "description": {
                "common": "glucagon intranasal increases toxicity of hyoscyamine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hyoscyamine spray",
            "description": {
                "common": "glucagon intranasal increases toxicity of hyoscyamine spray by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ipratropium",
            "description": {
                "common": "glucagon intranasal increases toxicity of ipratropium by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methscopolamine",
            "description": {
                "common": "glucagon intranasal increases toxicity of methscopolamine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "glucagon intranasal increases toxicity of orphenadrine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propantheline",
            "description": {
                "common": "glucagon intranasal increases toxicity of propantheline by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "scopolamine",
            "description": {
                "common": "glucagon intranasal increases toxicity of scopolamine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tiotropium",
            "description": {
                "common": "glucagon intranasal increases toxicity of tiotropium by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trihexyphenidyl",
            "description": {
                "common": "glucagon intranasal increases toxicity of trihexyphenidyl by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tropicamide",
            "description": {
                "common": "glucagon intranasal increases toxicity of tropicamide by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "umeclidinium bromide",
            "description": {
                "common": "glucagon intranasal increases toxicity of umeclidinium bromide by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "umeclidinium bromide/vilanterol inhaled",
            "description": {
                "common": "glucagon intranasal increases toxicity of umeclidinium bromide/vilanterol inhaled by Other (see comment). Avoid or Use Alternate Drug. \nComment: Coadministration of anticholinergic drugs and glucagon increase the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of acebutolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "glucagon intranasal increases effects of antithrombin alfa by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "glucagon intranasal increases effects of antithrombin III by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "argatroban",
            "description": {
                "common": "glucagon intranasal increases effects of argatroban by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of atenolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bemiparin",
            "description": {
                "common": "glucagon intranasal increases effects of bemiparin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of betaxolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of bisoprolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "glucagon intranasal increases effects of bivalirudin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of carvedilol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of celiprolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dalteparin",
            "description": {
                "common": "glucagon intranasal increases effects of dalteparin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and glucagon intranasal both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "glucagon intranasal increases effects of enoxaparin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of esmolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "glucagon intranasal increases effects of fondaparinux by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "heparin",
            "description": {
                "common": "glucagon intranasal increases effects of heparin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "indomethacin decreases effects of glucagon intranasal by unknown mechanism. Use Caution/Monitor. In patients taking indomethacin, glucagon may lose its ability to raise blood glucose or may even produce hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart protamine/insulin aspart",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin aspart protamine/insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin degludec by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin degludec/insulin aspart by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin detemir by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin glulisine by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin inhaled by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin isophane human/insulin regular human",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin isophane human/insulin regular human by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin lispro by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro protamine/insulin lispro",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin lispro protamine/insulin lispro by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin NPH by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "glucagon intranasal decreases effects of insulin regular human by pharmacodynamic antagonism. Use Caution/Monitor. Endogenous glucagon is a regulatory hormone that increases blood glucose levels; exogenous glucagon is often used to treat hypoglycemia in patients with diabetes mellitus."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of labetalol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "glucagon intranasal decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of metoprolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of nadolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of nebivolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of penbutolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenindione",
            "description": {
                "common": "glucagon intranasal increases effects of phenindione by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of pindolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of propranolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protamine",
            "description": {
                "common": "glucagon intranasal increases effects of protamine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of sotalol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "glucagon intranasal decreases toxicity of timolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium chloride",
            "description": {
                "common": "glucagon intranasal increases levels of magnesium chloride by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium citrate",
            "description": {
                "common": "glucagon intranasal increases levels of magnesium citrate by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium hydroxide",
            "description": {
                "common": "glucagon intranasal increases levels of magnesium hydroxide by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium oxide",
            "description": {
                "common": "glucagon intranasal increases levels of magnesium oxide by decreasing renal clearance. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "magnesium sulfate",
            "description": {
                "common": "glucagon intranasal increases levels of magnesium sulfate by decreasing renal clearance. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Watery eyes",
            "percent": "58.8"
        },
        {
            "name": "Nasal congestion",
            "percent": "42.5"
        },
        {
            "name": "Nasal itching",
            "percent": "39.2"
        },
        {
            "name": "Nausea",
            "percent": "26.1"
        },
        {
            "name": "Eye redness",
            "percent": "24.8"
        },
        {
            "name": "Itchy eyes",
            "percent": "21.6"
        },
        {
            "name": "Sneezing",
            "percent": "19.6"
        },
        {
            "name": "Headache",
            "percent": "18.3"
        },
        {
            "name": "Vomiting",
            "percent": "15"
        },
        {
            "name": "Upper respiratory tract irritation",
            "percent": "12.4"
        },
        {
            "name": "Throat itching",
            "percent": "12.4"
        },
        {
            "name": "Watery eyes",
            "percent": "47.2"
        },
        {
            "name": "Nasal congestion",
            "percent": "41.7"
        },
        {
            "name": "Vomiting",
            "percent": "30.6"
        },
        {
            "name": "Nasal itching",
            "percent": "27.8"
        },
        {
            "name": "Headache",
            "percent": "25"
        },
        {
            "name": "Runny nose",
            "percent": "25"
        },
        {
            "name": "Sneezing",
            "percent": "19.4"
        },
        {
            "name": "Upper respiratory tract irritation",
            "percent": "16.7"
        },
        {
            "name": "Itchy eyes",
            "percent": "16.7"
        },
        {
            "name": "Eye redness",
            "percent": "13.9"
        },
        {
            "name": "Throat itching",
            "percent": "2.8"
        },
        {
            "name": "Ears itching",
            "percent": "2.8"
        },
        {
            "name": "Ears itching",
            "percent": "3.3"
        },
        {
            "name": "Dysgeusia",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Additional upper respiratory tract irritation",
            "percent": null
        },
        {
            "name": "nasal pruritus",
            "percent": null
        },
        {
            "name": "throat irritation",
            "percent": null
        },
        {
            "name": "parosmia",
            "percent": null
        }
    ]
}